Current diagnostic methods for diseases often lack the sensitivity and specificity needed for early detection and personalized treatment, leading to delayed interventions and suboptimal patient outcomes. Traditional liquid biopsy techniques face challenges in identifying and validating novel biomarkers that can accurately reflect disease status and predict treatment response.

EVIIVE is developing a platform, IMPASS (Immune-Pathogenesis Surveillance System), that combines liquid biopsy analysis, machine learning, and biomarker discovery to enhance diagnostic and prognostic capabilities. The platform aims to improve the sensitivity and specificity of biomarker identification, enabling earlier disease detection and more personalized treatment strategies. By leveraging advanced machine learning algorithms and novel biomarker identification techniques, EVIIVE seeks to provide healthcare professionals with the tools to diagnose conditions at an early stage and tailor treatments to individual patient needs. The IMPASS platform analyzes extracellular vesicles to detect immune system defects. This approach aims to transform therapeutic strategies across a spectrum of diseases.

IMPASS platform integrates liquid biopsy analyses, advanced machine learning, and novel biomarker discovery.

Focus on extracellular vesicles (EVs) for biomarker identification.

Development of assay kits tailored for individualized treatment recommendations and disease tracking.

Aims to enhance the sensitivity and specificity of biomarker identification.

Machine learning models for improved diagnostic and prognostic power.

EVIIVE's primary target audience includes healthcare professionals, researchers, and industry-leading companies seeking advanced diagnostic and prognostic tools for personalized patient care.